This cluster groups 2 independently calculated changes: Cash & equivalents increased 4.1%; Operating cash flow increased 23.1%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTAptevo Therapeutics Inc.'s latest supported as-filed period reports revenue of $3.1M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 4.1%; Operating cash flow increased 23.1%.
2 evidence-backed componentsStock-based compensation changed +135.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 4 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
APVO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-381098SEC ↗8-KAug 21, 2026Period Aug 21, 20260001193125-26-361079SEC ↗10-QAug 14, 2026Period Jun 30, 20260001193125-26-350559SEC ↗8-KAug 14, 2026Period Aug 14, 20260001193125-26-350537SEC ↗8-KAug 13, 2026Period Aug 12, 20260001193125-26-349380SEC ↗4Aug 10, 2026Period Aug 6, 20260001193125-26-343080SEC ↗4Aug 10, 2026Period Aug 6, 20260001193125-26-343079SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed +23.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Shares outstanding changed -45.2% from the comparable as-filed period. The change ranks at the 38th percentile of 8 prior comparable changes.
Operating income changed -3.5% from the comparable as-filed period.
Research & development changed +11.1% from the comparable as-filed period.
Working capital / assets changed -98 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Current liabilities changed +6.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-343077